ANGO AngioDynamics
- 5.825
- +0.015+0.26%
AngioDynamics News
CEO, President & Director of AngioDynamics Picks Up 2.6% More Stock
Whilst it may not be a huge deal, we thought it was good to see that the AngioDynamics, Inc. (NASDAQ:ANGO) CEO, President & Director, James Clemmer, recently bought US$67k worth of stock, for US$6.70 per share.
AngioDynamics, Inc. (NASDAQ:ANGO) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
AngioDynamics, Inc. (NASDAQ:ANGO) shares have had a really impressive month, gaining 25% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses o
Insider Spends US$67k Buying More Shares In AngioDynamics
Insiders Buying Zumiez And 3 Other Stocks
Although U.S. stocks closed little changed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view
AngioDynamics(ANGO.US) Officer Buys US$67,000 in Common Stock
$AngioDynamics(ANGO.US)$ Officer Clemmer James C purchased 10,000 shares of common stock on Apr 8, 2024 at an average price of $6.7 for a total value of $67,000.Source: Announcement What is statement
AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript
Earnings Call: AngioDynamics Posts Mixed Q3 Results, Focuses on Growth
AngioDynamics (ticker: NASDAQ:ANGO), a medical device company, reported varied results in its fiscal year 2024 third-quarter earnings call.
AngioDynamics Third Quarter 2024 Earnings: Misses Expectations
AngioDynamics Inc (ANGO) Q3 2024 Earnings Call Transcript Highlights: Navigating Growth Amidst ...
Ocugen OCGN Phase 1⁄2 DSMB; AngioDynamics ANGO Analysts
Express News | AngioDynamics Shares Are Trading Higher After Oppenheimer Upgraded the Stock From Perform to Outperform and Announced a $12 Price Target
AngioDynamics (ANGO) Q3 Earnings and Revenues Miss Estimates
AngioDynamics Raised to Outperform From Perform by Oppenheimer
AngioDynamics Raised to Outperform From Perform by Oppenheimer
Express News | Oppenheimer Upgrades AngioDynamics to Outperform, Announces $12 Price Target
AngioDynamics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/05/2024 76.99% Oppenheimer → $12 Upgrades Perform → Outperform 01/09/2024 47.49% Raymond James $12 → $1
ATOS, SMR and EIGR Are Among Pre Market Gainers
AngioDynamics Stock Upgraded by Oppenheimer on FDA Approval, Strong Balance Sheet
FDA Clears AngioDynamics' AlphaVac F18 to Treat Pulmonary Embolism
Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential
Q3 2024 AngioDynamics Inc Earnings Call
Analysis
Price Target
No Data
